Malignant neoplasm of breast – Page 4

AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform

1 year ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Daiichi, Enhertu, Malignant neoplasm of breast, Nance-Horan syndrome, Nitroglycerin/Sodium Citrate/Ethanol Solution, Review Process Reform, Sankyo

Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform

G1 Therapeutics to Lay Off Staff After Cosela Fails in Pivotal Breast Cancer Study

1 year ago talkbio0Tagged Cosela, layoffs, Malignant neoplasm of breast, Metastatic Triple Negative, Phase 3 trial, trilaciclib, Well Differentiated

G1 Therapeutics, Cosela, Breast Cancer, Layoffs, Phase 3 Trial, Trilaciclib, Metastatic Triple Negative Breast Cancer

AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment

1 year ago talkbio0Tagged Antibody-Drug Conjugates, ASCO, AstraZeneca, Carcinoma breast stage IV, Daiichi, Deruxtecan, Enhertu, Malignant neoplasm of breast, Sankyo, trastuzumab

Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment

NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns

1 year ago talkbio0Tagged AstraZeneca, Cost Effectiveness, Coverage rejection, Daiichi Sankyo, Enhertu, Health Services, National, Malignant neoplasm of breast, Nitroglycerin/Sodium Citrate/Ethanol Solution, Technology

NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)